Bank of New York Mellon’s Palvella Therapeutics PVLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.67M | Buy |
30,587
+12,546
| +70% | +$1.52M | ﹤0.01% | 2478 |
|
|
2026
Q1 | $2.25M | Buy |
18,041
+1,777
| +11% | +$185K | ﹤0.01% | 2744 |
|
|
2025
Q4 | $1.7M | Buy |
16,264
+79
| +0.5% | +$6.74K | ﹤0.01% | 2937 |
|
|
2025
Q3 | $1.01M | Buy |
16,185
+2,523
| +18% | +$113K | ﹤0.01% | 3206 |
|
|
2025
Q2 | $308K | Buy |
+13,662
| New | +$321K | ﹤0.01% | 3787 |
|
|
2024
Q1 | – | Sell |
-499
| Closed | -$7.27K | – | 4333 |
|
|
2023
Q4 | $7.27K | Hold |
499
| – | – | ﹤0.01% | 4280 |
|
|
2023
Q3 | $11.9K | Hold |
499
| – | – | ﹤0.01% | 4284 |
|
|
2023
Q2 | $6.61K | Hold |
499
| – | – | ﹤0.01% | 4359 |
|
|
2023
Q1 | $39K | Hold |
499
| – | – | ﹤0.01% | 4237 |
|
|
2022
Q4 | $41.5K | Hold |
499
| – | – | ﹤0.01% | 4264 |
|
|
2022
Q3 | $46K | Sell |
499
-25
| -5% | -$3.22K | ﹤0.01% | 4340 |
|
|
2022
Q2 | $79K | Buy |
524
+25
| +5% | +$4.56K | ﹤0.01% | 4278 |
|
|
2022
Q1 | $121K | Sell |
499
-3
| -0.6% | -$789 | ﹤0.01% | 4369 |
|
|
2021
Q4 | $152K | Hold |
502
| – | – | ﹤0.01% | 4341 |
|
|
2021
Q3 | $208K | Buy |
502
+256
| +104% | +$89.1K | ﹤0.01% | 4203 |
|
|
2021
Q2 | $76K | Sell |
246
-1,300
| -84% | -$285K | ﹤0.01% | 4261 |
|
|
2021
Q1 | $318K | Sell |
1,546
-24
| -2% | -$5.25K | ﹤0.01% | 3884 |
|
|
2020
Q4 | $314K | Sell |
1,570
-94
| -6% | -$19.6K | ﹤0.01% | 3808 |
|
|
2020
Q3 | $275K | Buy |
1,664
+5
| +0.3% | +$1.14K | ﹤0.01% | 3750 |
|
|
2020
Q2 | $412K | Hold |
1,659
| – | – | ﹤0.01% | 3570 |
|
|
2020
Q1 | $303K | Sell |
1,659
-14
| -0.8% | -$3.53K | ﹤0.01% | 3593 |
|
|
2019
Q4 | $484K | Buy |
1,673
+142
| +9% | +$39.4K | ﹤0.01% | 3610 |
|
|
2019
Q3 | $418K | Buy |
1,531
+175
| +13% | +$67.8K | ﹤0.01% | 3640 |
|
|
2019
Q2 | $509K | Sell |
1,356
-77
| -5% | -$23K | ﹤0.01% | 3590 |
|
|
2019
Q1 | $384K | Hold |
1,433
| – | – | ﹤0.01% | 3650 |
|
|
2018
Q4 | $305K | Buy |
1,433
+9
| +0.6% | +$2.79K | ﹤0.01% | 3701 |
|
|
2018
Q3 | $638K | Buy |
1,424
+67
| +5% | +$29.1K | ﹤0.01% | 3522 |
|
|
2018
Q2 | $551K | Sell |
1,357
-1,076
| -44% | -$512K | ﹤0.01% | 3594 |
|
|
2018
Q1 | $1.33M | Buy |
2,433
+1,462
| +151% | +$905K | ﹤0.01% | 3051 |
|
|
2017
Q4 | $587K | Buy |
971
+25
| +3% | +$11.6K | ﹤0.01% | 3535 |
|
|
2017
Q3 | $436K | Buy |
946
+59
| +7% | +$25.2K | ﹤0.01% | 3635 |
|
|
2017
Q2 | $359K | Buy |
+887
| New | +$259K | ﹤0.01% | 3744 |
|
Other funds holding PVLA
SL
EA
EMFAT
Bank of New York Mellon's PVLA Position: Q2 2026 in Review
Bank of New York Mellon increased its Palvella Therapeutics (PVLA) stake by 70% in Q2 2026, buying an estimated $1.52M and bringing the position to 30,587 shares worth $4.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2478.
Bank of New York Mellon first reported a position in PVLA in Q2 2017 and has held it in 32 quarters since. 114 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.
- Bank of New York Mellon held 30,587 shares of Palvella Therapeutics worth $4.67M as of Q2 2026.
- Bank of New York Mellon bought 12,546 Palvella Therapeutics shares in Q2 2026, an estimated $1.52M.
- Palvella Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2478 holding.
- Bank of New York Mellon first reported a position in Palvella Therapeutics in Q2 2017 and has held it in 32 quarters since.
- 114 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.